Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1412)	2/18/2000 4:18:00 PM
From: nigel bates	Respond to of 4974

CORR getting greedy ? (it was only $150m a couple of days ago) - Feb. 18, 2000--COR Therapeutics, Inc. (Nasdaq:CORR - news) announced today the private placement of $250 million principal amount of 5% Convertible Subordinated Notes due 2007 (the ``Notes'). The Notes are convertible, subject to adjustment in certain circumstances, into COR Therapeutics' common stock at a price equal to $67.56 per share. The Company may also issue up to an additional $50 million of Notes to cover over-allotments in connection with the offering. Oh, and .. Feb. 18, 2000--ImClone Systems Incorporated (Nasdaq:IMCL - news) announced today that it intends to offer, subject to market and other conditions, $150 million principal amount of Convertible Subordinated Notes (plus an additional amount to cover over allotments if any) due 2005. Come on GLIA, before we the herd spends all its cash. nig